SCHEMBL4812656

SCHEMBL4812656

CC(=O)Oc1ccc(N2CCCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.57
MAPT P10636 9/20 0.54
ALDH1A1 P00352 9/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 3/20 0.54
GAA P10253 2/20 0.54
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
GFER P55789 1/20 0.53
LMNA P02545 2/20 0.52
POLB P06746 2/20 0.52
PKM P14618 1/20 0.52
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
HPGD P15428 3/20 0.51
HSD17B10 Q99714 3/20 0.51
TP53 P04637 2/20 0.51
TSHR P16473 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11035023 0.92 GLA (0.61) GLAMAPTALDH1A1KMT2AGAA
SCHEMBL9937342 0.86 GAA (0.57) GLAMAPTALDH1A1KMT2AKDM4E
SCHEMBL6554169 0.86 ALDH1A1 (0.58) GLAMAPTALDH1A1KMT2AKDM4E
SCHEMBL3903464 0.84 GFER (0.63) GLAMAPTALDH1A1KMT2AKDM4E
SCHEMBL3583532 0.84 GFER (0.63) GLAMAPTALDH1A1KMT2AGAA
SCHEMBL4543250 0.84 ADRB1 (0.62) GLAALDH1A1KDM4ELMNAHSD17B10
SCHEMBL15535616 0.83 CYP1A2 (0.54) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL4631828 0.83 GLA (0.51) GLAMAPTALDH1A1KMT2AGAA
SCHEMBL2172968 0.82 MAPT (0.56) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL8542788 0.81 ALDH1A1 (0.47) MAPTALDH1A1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320973-B2 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2008-01-22 US disclosed
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2004-06-10 US disclosed
EP-1403258-A1 DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE Ajinomoto Co., Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same CYP3A4, PPARD, CYP4B1 GLA 2019/4885MAPT 1722/4885ALDH1A1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.